All AbMole products are for research use only, cannot be used for human consumption.
Nutlin-3 is a small molecule inhibitor of the MDM2/p53 interaction, which leads to the non-genotoxic p53 stabilization, activation of cell cycle arrest and apoptosis pathways. Nutlin-3 inhibits the MDM2-p53 interaction with IC50 of 0.09 μM and synergistically activates p53 to suppress tumor growth. Nutlin-3 induces apoptosis in cancer cells. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM in cells with wild-type p53 such as HCT116, RKO and SJSA-1. Nutlin-3 is currently in phase I clinical trial for the treatment of retinoblastoma.
Ecotoxicol Environ Saf. 2022 Jun 1;237:113564.
Environmental BPDE induced human trophoblast cell apoptosis by up-regulating lnc-HZ01/p53 positive feedback loop
Nutlin-3 purchased from AbMole
 |
Source | Johann Wolfgang Goethe-Universität (2017). Figure 42. Nutlin (AbMole Bioscience; Houston, TX, USA) |
| Method | Western Blot | |
| Cell Lines | UKF-NB-3 und UKF-NB-6 Zellen | |
| Concentrations | 1 μM | |
| Incubation Time | 24 h | |
| Results | Auch hier ist durch die kombinierte Behandlung mit 10 nM YM155 und 1 μM Nutlin-3 eine 15-fache Erhöhung des p21 Proteinlevels in UKF-NB-3 zu beobachten. Ebenfalls erfolgt ein Anstieg der γH2A.X Expression |
 |
Source | Johann Wolfgang Goethe-Universität (2017). Figure 41. Nutlin (AbMole Bioscience; Houston, TX, USA) |
| Method | Western Blot | |
| Cell Lines | UKF-NB-3 und UKF-NB-6 Zellen | |
| Concentrations | 1 μM | |
| Incubation Time | 24 h | |
| Results | Anhand der Quantifizierung ist in Abb. 41 A zu erkennen, dass die Nutlin-3 Behandlung (1 μM) einen signifikanten Anstieg von p53 in UKF-NB-3 bewirkt (3-fach). |
 |
Source | Johann Wolfgang Goethe-Universität (2017). Figure 40. Nutlin (AbMole Bioscience; Houston, TX, USA) |
| Method | Western Blot | |
| Cell Lines | UKF-NB-3 und UKF-NB-6 Zellen | |
| Concentrations | 1 μM | |
| Incubation Time | 24 h | |
| Results | Um diesen Effekt genauer zu untersuchen, wurde im Western-Blot geprüft, inwiefern die kombinierte YM155 und Nutlin-3 Behandlung einen Einfluss auf die Expression entsprechender Proteine in UKF-NB-3 und UKF-NB-6 Zellen ausübt |
 |
Source | Johann Wolfgang Goethe-Universität (2017). Figure 39. Nutlin (AbMole Bioscience; Houston, TX, USA) |
| Method | Western Blot | |
| Cell Lines | UKF-NB-3 und UKF-NB-6 Zellen | |
| Concentrations | 1 μM | |
| Incubation Time | 24 h | |
| Results | Eine kombinierte Behandlung der UKF-NB-3 und UKF-NB-6 Zellen mit 0,625 nM YM155 und 1 μM Nutlin-3 zeigt einen signifikant verstärkenden Effekt in beiden Zelllinien |
 |
Source | Vitrual Biology (2015). Figure 3. Nutlin-3 |
| Method | Test for vitality with resazurin | |
| Cell Lines | NSCLC cells | |
| Concentrations | 30 μM | |
| Incubation Time | 24 h | |
| Results | On Figure 3 we selected several pathways that demonstrated an interesting dynamic in the change of significance (measured as -Log2(p-value)) of the moderately resistant cell lines in comparison with sensitive cell lines in different conditions with increased dosage of treatment by Nutlin-3. |
 |
Source | Vitrual Biology (2015). Figure 1. Nutlin-3 |
| Method | Test of sensitivity of NSCLC cells to Nutlin-3 | |
| Cell Lines | NSCLC cells | |
| Concentrations | 30 μM | |
| Incubation Time | 24 h | |
| Results | For further analysis we selected three cell lines: one, which was the most sensitive to Nutlin-3 – the H1944 cell line, and two, which were still reacting to Nutlin-3, but only under relatively high concentrations – H292 and A427 |
| Cell Experiment | |
|---|---|
| Cell lines | wild-type p53 (HCT116, RKO, and SJSA-1) and mutant p53 (MDA-MB-435 and SW480) cell lines |
| Preparation method | Effect of the enantiomers of Nutlin-3 on the growth and viability of cancer cells with wild-type p53 (HCT116, RKO, and SJSA-1) and mutant p53 (MDA-MB-435 and SW480). Cells were grown, treated, and analyzedAntiproliferative and cytotoxic activity of Nutlin-1. Exponentially growing cancer cells with wild-type p53 (HCT116, RKO, and SJSA-1) or mutant p53 (MDA-MB-435 and SW480) were incubated with a range of concentrations for 5 days and the cell mass and viability were measured by the MTT assay. |
| Concentrations | 0~30µM |
| Incubation time | 5 days |
| Animal Experiment | |
|---|---|
| Animal models | Nude mice bearing subcutaneous human cancer xenografts |
| Formulation | 2% Klucel, 0.5% Tween 80 |
| Dosages | 200 mg/kg twice daily for 3 weeks |
| Administration | oral gavage |
| Molecular Weight | 581.49 |
| Formula | C30H30Cl2N4O4 |
| CAS Number | 548472-68-0 |
| Solubility (25°C) | DMSO ≥ 50 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[2] Secchiero P, et al. Curr Pharm Des. Recent advances in the therapeutic perspectives of Nutlin-3.
| Related Mdm2 Products |
|---|
| MMRi64
MMRi64 disrupts Mdm2-MdmX interactions. |
| MeOIstPyrd
MeOIstPyrd is an anti-skin cancer agent. |
| MDM2/XIAP-IN-3
MDM2/XIAP-IN-3 is a dual MDM2/XIAP inhibitor. |
| UNP-6457
UNP-6457 is a potent active MDM2-p53 interaction inhibitor with an IC50 values of 8.9 nM. |
| YL93
YL93 is a dual inhibitors of MDM2/4 with Ki values of 0.64 μM and 1.1 nM for MDM4 and MDM2, respectively. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
